Pune, India -- (SBWIRE) -- 12/18/2017 -- Concordia International Corp., Eli Lilly and Company, Highland Therapeutics Inc., Janssen Global Services LLC, NEOS Therapeutics Inc., Novartis AG, Noven Pharmaceuticals Inc., Pfizer Inc., Shire, Teva Pharmaceutical are some of the prominent players at the forefront of competition in the Global ADHD Therapeutics Market and are profiled in MRFR Analysis.

ADHD Therapeutics – Market Overview

ADHD is one of the most common neurodevelopmental disorders of childhood. It is usually first diagnosed in childhood & often lasts into adulthood. Children with ADHD may have trouble paying attention, controlling impulsive behaviours or be hyperactive.

Growing paediatric population, increasing prevalence of ADHD, increasing awareness regarding ADHD are some of the factors responsible for the growth of the global ADHD therapeutics market.

Get a Sample Report @ https://www.marketresearchfuture.com/sample_request/1573 .

By seeing attractiveness of the market, market has witnessed, innovation followed by new launches. For example, Neos Therapeutics to launch Adzenys ER for ADHD in January 2018. FDA has approved Adzenys ER, an extended release oral suspension (amphetamine) for the treatment of attention-deficit hyperactivity disorder (ADHD) in patients age 6 or older. Neos Therapeutics of Dallas and Fort Worth, Texas, announced in a statement that the company plans to launch Adzenys ER in January 2018. Neos Therapeutics is the only company than can offer both branded amphetamine and methylphenidate therapies in extended release dosage forms. When it is available in 2018, Adenzys ER oral suspension will be the third Neos extended release product for ADHD from the company. It needs no refrigeration or reconstitution at the pharmacy. Another form of the product, Adzenys XR-ODT, is a disintegrating tablet. This FDA approval unlocks yet another treatment option for ADHD patients and their caregivers who are seeking a liquid extended release amphetamine product and provides a different dosage form of companys already-approved Adzenys XR-ODT.

Pipeline Development In ADHD: - Cingulate Therapeutics, LLC (CTx) is a privately held, clinical stage biopharmaceutical company focused on the development of innovative new products for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). Cingulate is developing two (2) proprietary, first-line medications, CTX-1301 (Dexmethylphenidate) and CTX-1302 (Dextroamphetamine), via the accelerated 505 (b)(2) regulatory pathway for the treatment of ADHD seeking indications for all patient segments: children, adolescents and adults. CTX-1301 and CTX-1302 utilize an innovative, flexible core tableting technology that enables the formulation and manufacturing of multi-cored tablets designed to deliver a rapid onset and last the entire active day while minimizing the afternoon crash and impact on sleep and appetite. The Company has completed its proof of concept trial in human subjects to validate the novel Target Product Profiles for both CTX-1301 and CTX-1302. After a planned submission of an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) in the first quarter of 2018, Cingulate intends to implement the full clinical plan for both CTX-1301 and CTX-1302 in 2018

ADHD Therapeutics Market – Competitive Analysis

As the market seems to be attractive, growing and profitable, at the same time market has witnessed intense rivalry among existing competitors. Many new entrants expected to enter into ADHD Therapeutics Market. There are many big players in the ADHD Therapeutics Market such as: Concordia International Corp., Eli Lilly and Company, Highland Therapeutics Inc., Janssen Global Services LLC, NEOS Therapeutics Inc., Novartis AG, Noven Pharmaceuticals Inc., Pfizer Inc., Shire, Teva Pharmaceutical

Order Single User License Copy of 80 Premium Pages is Available @ https://www.marketresearchfuture.com/reports/adhd-therapeutics-market-1573 .

ADHD Therapeutics Market – Regional Analysis

Geographically, the global ADHD therapeutics market is segmented into four major regions such as: North America, Europe, and Asia-Pacific & Rest of the World. North America is estimated to dominate the global ADHD therapeutics market, with a maximum value share of the overall market. Followed by European region due to highly developed healthcare industry, high disposable income, ongoing clinical trials & early approval of drugs. However, Asia Pacific market is also witnessing a very strong growth due to high rate of development in healthcare industry, government initiatives for treatment of mental illness and increasing prevalence of mental disorders.

Brief TOC

Introduction
Research Methodology
Market Dynamics
Market Factor Analysis
Global ADHD Therapeutics Market, By Drug Type
Global ADHD Therapeutics Market, By Age Group
Global ADHD Therapeutics Market, By End Users
Global ADHD Therapeutics Market, By Region
Competitive Landscape
Company Profile
Conclusion
Appendix

Ask to Expert @ https://www.marketresearchfuture.com/enquiry/1573 .

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.